Data from large cohorts show that mTOR inhibitors have antineoplastic effects and may reduce the risk of new cancers and improve outcomes in existing neoplasms, including post-transplant; however, real-world use remains limited and frequently discontinued due to adverse effects, making individualized selection for conversion crucial [41,42]. Here, MTOR is linked to cancer.